Ocular Therapeutix, Inc. Common Stock OCUL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:01:31.066Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:51:58.815316294Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T03:01:30.676985+00:00
Ocular Therapeutix, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.74 | 569.3% | 46.0% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 7.23 | 215.7% | 10.9% | |||
| 55Δ | 7.62 | 229.0% | 9.8% | |||
| 60Δ | 8.02 | 241.7% | 8.6% | |||
| 65Δ | 8.44 | 236.7% | 7.3% | |||
| 70Δ | 6.00 | 235.6% | 8.6% | 8.86 | 231.8% | 6.0% |
| 75Δ | 5.62 | 246.2% | 7.1% | 9.28 | 226.9% | 4.6% |
| 80Δ | 5.23 | 256.8% | 5.5% | 9.71 | 221.9% | 3.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.74
- IV
- 569.3%
- B/E move
- 46.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.23
- IV
- 215.7%
- B/E move
- 10.9%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.62
- IV
- 229.0%
- B/E move
- 9.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.02
- IV
- 241.7%
- B/E move
- 8.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.44
- IV
- 236.7%
- B/E move
- 7.3%
70Δ
- Pseudo strike
- 6.00
- IV
- 235.6%
- B/E move
- 8.6%
- Pseudo strike
- 8.86
- IV
- 231.8%
- B/E move
- 6.0%
75Δ
- Pseudo strike
- 5.62
- IV
- 246.2%
- B/E move
- 7.1%
- Pseudo strike
- 9.28
- IV
- 226.9%
- B/E move
- 4.6%
80Δ
- Pseudo strike
- 5.23
- IV
- 256.8%
- B/E move
- 5.5%
- Pseudo strike
- 9.71
- IV
- 221.9%
- B/E move
- 3.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 114.35% | |
| 91.50% | |
| 129.09% | |
| 72.91% | |
| 104.24% | |
| 101.43% | |
| 94.71% | |
| 121.55% | |
| 94.34% | |
| 93.15% |
Biotechnology
OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company…
More →OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting…
More →ONC
Description unavailable
More →ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San…
More →ORKA
Oruka Therapeutics, Inc. is a biotechnology company.
More →ORMP
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or…
More →